ThromboGenics NV's licensing deal with Rhein Minapharma Biogenetics for preclinical THR-174 could bring a next-generation thrombolytic for developing countries, a cheaper therapy for heart attacks that's equivalent to the gold standard tissue plasminogen activator (tPA). (BioWorld Today)